All In Biotech

Drug Trial Radar · NCT05255302

De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

A Phase II-III Randomized Trial Evaluating Maintenance Pembrolizumab (± Pemetrexed) Until Progression Versus Observation (± Pemetrexed) After 6 Months of Platinum-based Doublet Chemotherapy Plus Pembrolizumab Induction Treatment in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Last checked: Nov 20, 2026Latest source record: Apr 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,360 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,360

Planned (sponsor's estimate)

Start

May 2, 2022

Primary completion

May 2025

Study completion Jun 1, 2029

Sponsor

Lead sponsor
Intergroupe Francophone de Cancerologie ThoraciqueAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Immunotherapeutic approaches recently have demonstrated clinical efficacy in several cancer types, including melanoma and NSCLC. As a matter of fact, first registration trials of immune-checkpoints inhibitors (ICI) in second-line settings (pembrolizumab as well as nivolumab or atezolizumab) had stated that ICI could be continued until disease progression or not tolerable toxicity, up to 5 years. This is only for the first-line registration studies that the arbitrary maximal duration of treatment of 2 years was set up by the Companies sponsoring such trials. The aim is to study a de-escalation scheme of treatment from 2 years of immunotherapy to 6 months (27-weeks), in patients with controlled disease.

Conditions

  • Metastatic NSCLC

Interventions

  • Pembrolizumab before randomizationDrug

    Pembrolizumab 200 mg every 3 weeks before randomization

  • ChemotherapyDrug

    Platinum doublet - 4 cycles: either paclitaxel-carboplatin for patient with SCC or pemetrexed-platinum salt followed by 2 cycles of pemetrexed until reaching the 6 months time-point for randomization Carboplatin AUC 5 for non-squamous cell carcinoma and AUC6 for squamous cell carcinoma every 3 weeks or cisplatin 75 mg/m² every 3 weeks Pemetrexed 500 mg/m² every 3 weeks or paclitaxel 175 mg/m² every 3 weeks

  • PemetrexedDrug

    Maintenance pemetrexed after randomization Pemetrexed 500 mg/m² every 3 weeks

  • Pembrolizumab after randomizationDrug

    Pembrolizumab 200 mg every 3 weeks after randomization

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase II: 18-month overall survival (OS)Time frame: 18 months after inclusion
  2. Phase III: overall survivalTime frame: about 24 months after randomization

Locations

44 sites in 1 country. Site status is shown where the registry gives one.

  • Aix-en-Provence - CH

    Aix-en-Provence, France · Not yet recruiting

  • Amiens - Clinique de l'Europe

    Amiens, France · Not yet recruiting

  • Angers - CHU

    Angers, France · Not yet recruiting

  • Avignon - CH

    Avignon, France · Not yet recruiting

  • Besançon - CHU

    Besançon, France · Not yet recruiting

  • Bordeaux - Polyclinique

    Bordeaux, France · Not yet recruiting

  • CHU de Bordeaux

    Bordeaux, France · Not yet recruiting

  • Caen - CHU Côte de Nacre

    Caen, France · Recruiting

  • Cannes - CH

    Cannes, France · Not yet recruiting

  • Chauny - Centre Hospitalier

    Chauny, France · Not yet recruiting

  • CH

    Colmar, France · Not yet recruiting

  • Centre Georges François Leclerc

    Dijon, France · Not yet recruiting

  • CHRU Grenoble

    Grenoble, France · Active not recruiting

  • La Roche Sur Yon - CH

    La Roche-sur-Yon, France · Not yet recruiting

  • CH de Versailles

    Le Chesnay, France · Not yet recruiting

  • Centre Hospitalier - Pneumologie

    Le Mans, France · Not yet recruiting

  • CHRU de Lille

    Lille, France · Not yet recruiting

  • CHU de Limoges

    Limoges, France · Not yet recruiting

  • Lyon - Hôpital Jean Mermoz

    Lyon, France · Not yet recruiting

  • Marseille - Hôpital Européen

    Marseille, France · Not yet recruiting

  • Meaux - CH

    Meaux, France · Not yet recruiting

  • Metz - Hôpital Robert Schuman

    Metz, France · Active not recruiting

  • Hôpital Arnaud de Villeneuve

    Montpellier, France · Not yet recruiting

  • Centre Hospitalier

    Mulhouse, France · Not yet recruiting

  • Nantes - CHU Hôpital Laënnec

    Nantes, France · Not yet recruiting

  • Nice - CRLCC

    Nice, France · Not yet recruiting

  • Orléans - CHR

    Orléans, France · Not yet recruiting

  • Paris - APHP - Hopital Tenon

    Paris, France · Active not recruiting

  • Institut CURIE

    Paris, France · Not yet recruiting

  • Hôpital Bichat - Claude - Bernard

    Paris, France · Recruiting

  • Reims - CHU

    Reims, France · Not yet recruiting

  • Rouen - CHU

    Rouen, France · Not yet recruiting

  • Centre René Huguenin

    Saint-Cloud, France · Not yet recruiting

  • CHU Saint-Etienne Pneumologie

    Saint-Etienne, France · Not yet recruiting

  • Hôpital privé de la Loire

    Saint-Etienne, France · Not yet recruiting

  • Institut de Cancérologie de l'Ouest - René Gauducheau

    Saint-Herblain, France · Not yet recruiting

  • Saint-Nazaire - Clinique Mutualiste de l'Estuaire

    Saint-Nazaire, France · Not yet recruiting

  • CHU de La Réunion-Site Sud

    Saint-Pierre, France · Not yet recruiting

  • Centre Hospitalier

    Saint-Quentin, France · Not yet recruiting

  • Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg

    Strasbourg, France · Not yet recruiting

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.